Chinese Journal of Radiological Medicine and Protection 2017;37(3):216-221
doi:10.3760/cma.j.issn.0254-5098.2017.03.011
Dosimetric comparison of TomoDirect and TomoHelical modalities in Tomotherapy system for left-breast cancer radiotherapy after breast-conserving surgery
Jinyong LIN ; Cairong HU ; Xiuchun ZHANG ; Jun LU ; Penggang BAI ; Mingzhi ZHENG ; Jihong CHEN ; Yanming CHENG ; Junxin WU ; Jianji PAN
Keywords
Left-breast cancer; Radiotherapy after breast-conserving surgery; TomoDirect; TomoHelical; Dosimetry
Country
China
Language
Chinese
Abstract
Objective To compare the dosimetric difference among plans designed by 4-field,6-field TomoDirect and TomoHelical techniques in Tomotherapy system for left-breast cancer patients with radiotherapy after breast-conserving surgery.Method A total of 16 patients with left-breast cancer following breast-conserving surgery and intensity-modulated radiation therapy were enrolled in this retrospective study.The 4-field TomoDirect (TD4),6-field TomoDirect (TD6),and TomoHelical (TH) techniques were applied to design simulation plans in tomotherapy system for each patient,respectively.The differences of dose distribution and treatment parameters were analyzed in this study.Results Three plans all met the clinical requirement.Thereinto,TD4 was superior to TH in the dose limitation of organs at risk (OARs),especially the max dose of cord and right-breast,thc 5 Gy radiation volume of lung,and the mean dose of heart(F =595.60,129.24,60.44,65.37,P < 0.05),but inferior to TH in dose homogeneity (HI) and conformity (CI) (F =2.78,60.93,P < 0.05).However,TD6 improved TD4's HI and CI when delivered the lower OARs dose compared to TH.Meanwhile,the number of monitor units was less in TD technique and reduced the treatment times (F =24.89,3.75,P < O.05).Conclusions For the radiotherapy of left-breast cancer patients after breast-conserving surgery,TD6 technique appeared to be superior,with the lower radiation dose of OARs compared to TH technique,and the better target's HI and CI in comparison with TD4 technique,especially in patients with early stage breast cancer.
备案号: 11010502037788, 京ICP备10218182号-8)